Appendix 1 (as supplied by authors): International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) Format Coding Used for Cohort Formation and Formation of Study Covariates

- 1. Coding for exclusion criteria in cohort formation. Exclusion criteria was assess in the one-year period prior to index date (defined in the manuscript). A broad set of ICD-9-CM coding was used to exclude as many patients as possible with prior conditions of the kidney. Coding was obtained from a large number of validation studies from the following two systematic reviews for diseases of the kidney [1-2]
 - 250.40: Diabetes mellitus with renal manifestation, type II or unspecified type, not stated as uncontrolled
 - 250.41: Diabetes mellitus with renal manifestation, type I not stated as uncontrolled
 - 250.42: Diabetes mellitus with renal manifestation, type II or unspecified type, uncontrolled
 - 250.43: Diabetes mellitus with renal manifestation, type I uncontrolled
 - 403.11: Benign hypertensive renal disease with renal failure
 - 403.91: Unspecified hypertensive renal disease with renal failure
 - 404.13: Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease
 - 404.92: Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease
 - 404.93: Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease
 - 581.0: Nephrotic syndrome with lesion of proliferative glomerulonephritis
 - 581.1: Nephrotic syndrome with lesion of membranous glomerulonephritis
 - 581.2: Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis
 - 581.3: Nephrotic syndrome with lesion of minimal change glomerulonephritis
 - 581.81: Nephrotic syndrome in diseases classified elsewhere
 - 581.89: Other nephrotic syndrome with specified pathological lesion in kidney
 - 582.1: Chronic glomerulonephritis with lesion of membranous glomerulonephritis
 - 582.2: Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis
 - 582.81: Chronic glomerulonephritis in diseases classified elsewhere
 - 582.89: Other chronic glomerulonephritis with specified pathological lesion in kidney
 - 582.9: Chronic glomerulonephritis with unspecified pathological lesion in kidney
 - 583.0: Nephritis and nephropathy not specified as acute or chronic with lesion of proliferative glomerulonephritis
 - 583.6: Nephritis and nephropathy not specified as acute or chronic with lesion of renal cortical necrosis
 - 583.81: Nephritis and nephropathy not specified as acute or chronic in diseases classified elsewhere
 - 583.89: Other nephritis and nephropathy not specified as acute or chronic with specified pathological lesion in kidney

Appendix to: Bird ST, Etminan M, Brophy JM, et al. Risk of acute kidney injury associated with the use of fluoroquinolones. *CMAJ* 2013. DOI:10.1503/cmaj.121730. Copyright © 2013 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

- 583.9: Nephritis and nephropathy not specified as acute or chronic with unspecified pathological lesion in kidney
- 584.0: Acute renal failure ARF, unspecified
- 584.5: Acute tubular necrosis
- 584.6: Cortical ARF
- 584.7: Medullary ARF
- 584.8: ARF with other specified pathologic lesion
- 584.9: ARF not otherwise specified
- 585: Renal failure chronic
- 585.1: Chronic kidney disease stage I
- 585.2: Chronic kidney disease stage II
- 585.3: Chronic kidney disease stage III
- 585.4: Chronic kidney disease stage IV
- 585.5: Chronic kidney disease stage V
- 585.6: End stage renal disease
- 585.9: Chronic kidney disease unspecified
- 586: Renal failure unspecified
- 587: Renal sclerosis unspecified
- 588: Disorders resulting from impaired renal function
- 588.0: Renal osteodystrophy
- 588.1: Nephrogenic diabetes insipitus
- 588.8: Other specified disorders resulting from impaired renal function
- 588.81: Secondary hyperparathyroidism (of renal origin)
- 288.89: Other specified disorders resulting from impaired renal function
- 588.9: Unspecified disorder resulting from impaired renal function
- V42.0: Kidney replaced by transplant
- V45.1: Postsurgical renal dialysis status
- V56.2: Fitting and adjustment of peritoneal dialysis catheter
- V56.0: Aftercare involving extracorporeal dialysis
- V56.31: Encounter for adequacy testing for hemodialysis
- V56.32: Encounter for adequacy testing for peritoneal dialysis
- V56.8: Encounter for other dialysis

2. Coding for the study outcome of acute renal failure. ICD-9-CM codes were obtained from validation studies as described in the text of the manuscript [3-4]

584.0 (acute renal failure (ARF), unspecified)

584.5 (acute tubular necrosis)

584.6 (cortical ARF)

584.7 (medullary ARF)

584.8 (ARF with other specified pathologic lesion)

584.9 (ARF not otherwise specified).

3. Coding used for covariate formation

Cancer (Coding obtained from the Charlson Comorbidity Score [5-6])

140:	Malignant neoplasm of lip
141:	Malignant neoplasm of tongue
142:	Malignant neoplasm of major salivary glands
143:	Malignant neoplasm of gum
144:	Malignant neoplasm of floor of mouth
145:	Malignant neoplasm of other and unspecified parts of mouth
146:	Malignant neoplasm of oropharynx
147:	Malignant neoplasm of nasopharynx
148:	Malignant neoplasm of hypopharynx
149:	Malignant neoplasm of other and ill-defined sites within the lip oral cavity and pharynx
150:	Malignant neoplasm of esophagus
151:	Malignant neoplasm of stomach
152:	Malignant neoplasm of small intestine including duodenum
153:	Malignant neoplasm of colon
154:	Malignant neoplasm of rectum rectosigmoid junction and anus
155:	Malignant neoplasm of liver and intrahepatic bile ducts
156:	Malignant neoplasm of gallbladder and extrahepatic bile ducts
157:	Malignant neoplasm of pancreas
158:	Malignant neoplasm of retroperitoneum and peritoneum
159:	Malignant neoplasm of other and ill-defined sites within the digestive organs and
	peritoneum
160:	Malignant neoplasm of nasal cavities middle ear and accessory sinuses
161:	Malignant neoplasm of larynx
162:	Malignant neoplasm of trachea bronchus and lung
163:	Malignant neoplasm of pleura
164:	Malignant neoplasm of thymus heart and mediastinum
165:	Malignant neoplasm of other and ill-defined sites within the respiratory system and
	intrathoracic organs
170:	Malignant neoplasm of bone and articular cartilage
171:	Malignant neoplasm of connective and other soft tissue
172:	Malignant melanoma of skin
175:	Malignant neoplasm of male breast
176:	Kaposi's sarcoma
179:	Malignant neoplasm of uterus, part unspecified
180:	Malignant neoplasm of cervix uteri
181:	Malignant neoplasm of placenta
182:	Malignant neoplasm of body of uterus
183:	Malignant neoplasm of ovary and other uterine adnexa
185:	Malignant neoplasm of prostate
186:	Malignant neoplasm of testis
187:	Malignant neoplasm of penis and other male genital organs

188:	Malignant neoplasm of bladder
189:	Malignant neoplasm of kidney and other and unspecified urinary organs
190:	Malignant neoplasm of eye
191:	Malignant neoplasm of brain
192:	Malignant neoplasm of other and unspecified parts of nervous system
193:	Malignant neoplasm of thyroid gland
194:	Malignant neoplasm of other endocrine glands and related structures
195:	Malignant neoplasm of other and ill-defined sites
200:	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of
	lymphatic tissue
2∩1・	Hadgkin's disassa 201

Hodgkin's disease 201 201:

Multiple myeloma and immunoproliferative neoplasms 203:

205: Myeloid leukemia 206: Monocytic leukemia 207: Other specified leukemia

208: Leukemia of unspecified cell type

Congestive Heart Failure (Coding obtained from the Charlson Comorbidity Score [5-6])

428: **Heart Failure**

Diabetes Mellitus (Coding obtained from the Charlson Comorbidity Score [5-6])

250: Diabetes mellitus

Human Immunodeficiency Virus (Coding obtained from the Charlson Comorbidity Score [5-6])

042: Human Immunodeficiency Virus [HIV] disease

Hypertension

401: **Essential Hypertension**

Genitourinary Infection

**broad ICD-9-CM coding for a specific organ class was used in combination with a fluroquinolone prescription to best identify the indication for prescribing

590: Infections of kidney

595: Cystitis

599: Other disorders of urethra and urinary tract

Respiratory Infection

**broad ICD-9-CM coding for a specific organ class was used in combination with a fluroquinolone prescription to best identify the indication for prescribing

- 017: Tuberculosis of skin and subcutaneous cellular tissue, unspecified031: Diseases due to mycobacteria
- 034: Streptococcal sore throat and scarlet fever
- 135: Sarcoidosis
- 460: Acute nasopharyngitis
- 461: Acute sinusitis
- 462: Acute pharyngitis
- 463: Acute tonsillitis
- 464: Acute laryngitis and tracheitis
- 465: Acute upper respiratory infections of multiple or unspecified sites
- 466: Acute bronchitis and bronchiolitis
- 471: Nasal polyps
- 472: Chronic pharyngitis and nasopharyngitis
- 473: Chronic sinusitis
- 474: Chronic disease of tonsils and adenoids
- 475: Peritonsillar abscess
- 476: Chronic laryngitis and laryngotracheitis
- 478: Other diseases of upper respiratory tract
- 481: Pneumococcal pneumonia
- 482: Other bacterial pneumonia
- 483: Pneumonia due to other specified organism
- 484: Pneumonia in infectious diseases classified elsewhere
- 485: Bronchopneumonia, organism unspecified
- 486: Pneumonia, organism unspecified
- 490: Bronchitis, not specified as acute or chronic
- 491: Chronic bronchitis
- 507: Pneumonitis due to solids and liquids
- 511: Pleurisy
- 513: Abscess of lung and mediastinum
- 514: Pulmonary congestion and hypostasis
- 515: Postinflammatory pulmonary fibrosis
- 516: Other alveolar and parietoalveolar pneumonopathy
- 517: Lung involvement in conditions classified elsewhere
- 518: Other diseases of lung
- 519: Other diseases of respiratory system

Gastrointestinal Infection

**broad ICD-9-CM coding for a specific organ class was used in combination with a fluroquinolone prescription to best identify the indication for prescribing

003: Other salmonella infections

005: Other food poisoning (bacterial)

008: Intestinal infections due to other organisms

009:	Ill-defined intestinal infections
085:	Leishmaniasis

041: Bacterial infection in conditions classified elsewhere and of unspecified site

531: Gastric ulcer532: Duodenal ulcer

533: Peptic ulcer site unspecified

535: Gastritis and duodenitis

536: Disorders of function of stomach

537: Other disorders of stomach and duodenum

538: Gastrointestinal mucositis (ulcerative)

555: Regional enteritis

556: Ulcerative enterocolitis

562: Diverticula of intestine

564: Functional digestive disorders not elsewhere classified

567: Peritonitis and retroperitoneal infections

568: Other disorders of peritoneum569: Other disorders of intestine

Skin and Soft Tissue Infection

**broad ICD-9-CM coding for a specific organ class was used in combination with a fluroquinolone prescription to best identify the indication for prescribing

035: Erysipelas

680: Carbuncle and furuncle

681: Cellulitis and abscess of finger and toe

682: Other cellulitis and abscess

684: Impetigo

686: Other local infection of skin and subcutaneous tissue

691: Atopic dermatitis and related conditions

692: Contact dermatitis and other eczema

694: Bullous dermatoses

695: Erythematous conditions

696: Other psoriasis

698: Pruritus and related conditions

700: Corns and callosities

701: Other hypertrophic and atrophic conditions of the skin

702: Other dermatoses

707: Chronic ulcer of skin

528: Diseases of the oral soft tissues excluding lesions specific for gingiva and tongue

893: Open wound of toe(s)

Joint or Bone Infection

**broad ICD-9-CM coding for a specific organ class was used in combination with a fluroquinolone prescription to best identify the indication for prescribing

- 730: Osteomyelitis periostitis and other infections involving bone
- 731: Osteitis derormans and osteopathies associated with other disorders classified elsewhere

References

- [1] Grams ME, Plantinga LC, Hedgeman E, et al. Validation of CKD and related conditions in existing data sets: a systematic review. Am J Kidney Dis 2011;57:44-54.
- [2] Vlasschaert ME, Bejaimal SA, Hackam DG, et al. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis 2011;57:29-43.
- [3] Waikar SS, Wald R, Chertow GM, et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. *J Am Soc Nephrol* 2006;17(6):1688-94.
- [4] Liangos O, Wald R, O'Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of AKI in hospitalized patients: a national survey. *Clin J Am Soc Nephrol* 2006;1(1):43-51.
- [5] Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45:613-9.
- [6] Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining Comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;43(11):1130-9.